Stock Information

 

In this section you will find detailed information regarding the Evotec SE share, ranging from basic share data over stock charts, shareholder structure, our financial analysts, our auditors to our dividend policy.  

 

Basic Share Data

Listing on Frankfurt Stock Exchange (XETRA)
Listing NASDAQ, New York
Security identification numbers
 
Ordinary bearer shares
ISIN: DE0005664809
 

American Depositary Shares (“ADSs”)
ISIN:
US30050E1055

Ticker symbol

Frankfurt Stock Exchange: EVT


NASDAQ: EVO

Bloomberg Xetra: EVT GY Equity

Reuters Xetra: EVTG.DE

Stock exchange

Frankfurt Stock Exchange
NASDAQ New York
Segment
Prime Standard
Global Select Market
Index
MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX
n/a
Designated Sponsor
ODDO SEYDLER BANK AG
Paying agent
Deutsche Bank AG, Frankfurt am Main
J.P. Morgan
Number of shares issued
177,185,736 ordinary bearer shares
22,995,000 ADSs (11,497,500 ordinary shares)

Nominal capital

€ 177,185,736
€ 177,185,736
Security identification numbers
 
Listing on Frankfurt Stock Exchange (XETRA)
Ordinary bearer shares
ISIN: DE0005664809
 
Listing NASDAQ, New York

American Depositary Shares (“ADSs”)
ISIN:
US30050E1055

Ticker symbol

Listing on Frankfurt Stock Exchange (XETRA)

Frankfurt Stock Exchange: EVT


Listing NASDAQ, New York

NASDAQ: EVO

Bloomberg Xetra: EVT GY Equity

Reuters Xetra: EVTG.DE

Stock exchange

Listing on Frankfurt Stock Exchange (XETRA) Frankfurt Stock Exchange
Listing NASDAQ, New York NASDAQ New York
Segment
Listing on Frankfurt Stock Exchange (XETRA) Prime Standard
Listing NASDAQ, New York Global Select Market
Index
Listing on Frankfurt Stock Exchange (XETRA) MDAX, TecDAX, Prime All Share, LTecDAX, Technology All Share, CDAX
Listing NASDAQ, New York n/a
Designated Sponsor
Listing on Frankfurt Stock Exchange (XETRA) ODDO SEYDLER BANK AG
Listing NASDAQ, New York
Paying agent
Listing on Frankfurt Stock Exchange (XETRA) Deutsche Bank AG, Frankfurt am Main
Listing NASDAQ, New York J.P. Morgan
Number of shares issued
Listing on Frankfurt Stock Exchange (XETRA) 177,185,736 ordinary bearer shares
Listing NASDAQ, New York 22,995,000 ADSs (11,497,500 ordinary shares)

Nominal capital

Listing on Frankfurt Stock Exchange (XETRA) € 177,185,736
Listing NASDAQ, New York € 177,185,736

Listing on NASDAQ

Since November 2021 Evotec SE is listed on NASDAQ (Ticker Symbol: EVO).

Please find all further information regarding the NASDAQ listing as well as al published filings of Evotec SE under the following link:

Link to SEC/EDGAR

Stock Price & Chart

Shareholder structure

On 31 October 2022, the number of total voting rights amounts to 176,952,653.

Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), shareholders of a listed German company are required to notify the Company and the German Federal Financial Supervisory Authority (BaFin) of any change to the voting interest in Evotec SE whenever it reaches, exceeds or falls below specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50% or 75% of the voting rights). Evotec’s voting rights announcements can be found at dgap.de.

Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 73% according to our estimates (Evotec: 11|2022).

 

Shareholder structure (in %)*

* Rounding differences may occur.

Analysts

Overview of analysts covering the Evotec share

Bank of America Derik de Bruin

 

BofA Securities

NYI-100-16-03

One Bryant Park

New York, NY  10036

 

Bryan Garnier & Co Alex Cogut

92, avenue des Champs-Elysées, 75008 Paris, France

Citigroup Inc. Peter Verdult
One Court Square, 45th Floor, Long Island City, New York 11120, USA
Cowen Steven Mah

 Two International Place, Boston, MA 02110

Deutsche Bank Falko Friedrichs
Große Gallusstraße 10-14, 60311 Frankfurt am Main
EQUI.TS GmbH Thomas Schiessle
Am Schieferstein 1, 60435 Franfkurt am Main
H.C. Wainwright & Co. Douglas Tsao

H.C. Wainwright & Company, Inc.

430 Park Ave., 4th Fl.

New York, New York, 10022

United States

Intron Health Naresh Chouhan
New Street Research LLP, 11 Austin Friars, London, EC2N 2HG
Jefferies Peter Welford

Jefferies, 520 Madison Avenue, New York, NY 10022

Morgan Stanley James Quigley

Morgan Stanley & Co. LLC, 1585 Broadway Avenue, New York, NY 10036

 

ODDO BHF Stephan Wulf
Bockenheimer Landstraße 10, 60323 Frankfurt am Main, Germany
Royal Bank of Canada (RBC) Zoe Karamanoli

Royal Bank of Canada Europe Ltd.,
100 Bishopsgate, London, EC2N 4AA, UK

Rx Securities Dr Samir Devani
1 Fore Street, Moorgate, Third Floor, London EC2Y 9DT, United Kingdom
Van Lanschot Kempen Sebastiaan van der Schoot

Beethovenstraat 300, 1077 WZ Amsterdam, The Netherlands

Warburg Research Dr Christian Ehmann
Ferdinandstraße 75, 20095 Hamburg, Germany

Latest analyst recommendations

Below you will find the latest analyst recommendations.

Analyst
Recommendation
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
Target Price of ADS listed at NASDAQ New York
(in USD)
Date of latest
Research Report
Bryan Garnier & Co
BUY
22.00 EUR
-
29 September 2022
Citigroup Inc.
NEUTRAL/HIGH RISK
21.00 EUR
-
10 November 2022
Cowen
OUTPERFORM
50.00 EUR
28.00 USD
16 December 2022
Deutsche Bank
HOLD
21.00 EUR
-
16 December 2022
H.C.Wainwright & Co
BUY
-
12.00 USD
27 January 2023
Jefferies
BUY
34.00 EUR
-
10 November 2022
Morgan Stanley
UNDERWEIGHT
22.00 EUR
-
09 November 2022
ODDO BHF
OUTPERFORM
23.00 EUR
-
09 January 2023
Royal Bank of Canada (RBC)
OUTPERFORM
28.00 EUR
-
28 November 2022
Rx Securities
BUY
35.00 EUR
-
09 November 2022
Van Lanschot Kempen
BUY
23.00 EUR
-
21 December 2022
Warburg Research
BUY
29.00 EUR
-
24 January 2023
Average target price
28.00 EUR
20.00 USD
Analyst Bryan Garnier & Co
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
22.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
29 September 2022
Analyst Citigroup Inc.
Recommendation NEUTRAL/HIGH RISK
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
21.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
10 November 2022
Analyst Cowen
Recommendation OUTPERFORM
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
50.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
28.00 USD
Date of latest
Research Report
16 December 2022
Analyst Deutsche Bank
Recommendation HOLD
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
21.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
16 December 2022
Analyst H.C.Wainwright & Co
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
-
Target Price of ADS listed at NASDAQ New York
(in USD)
12.00 USD
Date of latest
Research Report
27 January 2023
Analyst Jefferies
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
34.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
10 November 2022
Analyst Morgan Stanley
Recommendation UNDERWEIGHT
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
22.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
09 November 2022
Analyst ODDO BHF
Recommendation OUTPERFORM
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
23.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
09 January 2023
Analyst Royal Bank of Canada (RBC)
Recommendation OUTPERFORM
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
28.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
28 November 2022
Analyst Rx Securities
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
35.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
09 November 2022
Analyst Van Lanschot Kempen
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
23.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
21 December 2022
Analyst Warburg Research
Recommendation BUY
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
29.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
-
Date of latest
Research Report
24 January 2023
Analyst Average target price
Recommendation
Target price of Shares listed at Frankfurt Stock Exchange
(in EUR)
28.00 EUR
Target Price of ADS listed at NASDAQ New York
(in USD)
20.00 USD
Date of latest
Research Report

 

Important Notice:

Evotec is covered and evaluated by the analysts mentioned above. Please note that any opinions, estimates or forecasts regarding Evotec's performance made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Evotec or its management. The above reference to the analysts does not imply that Evotec endorses their opinions. Evotec is under no obligation to update or supplement the information provided above and does not guarantee the accuracy or completeness of this list.

Copies of the reports from the analysts listed above can be obtained directly from the analysts or their employers. Due to legal requirements, Evotec is not allowed to publish the analyst reports. 

 

Evotec's Dividend Policy

The payment of dividends depends on Evotec’s financial situation and liquidity requirements, general market conditions, and statutory, tax and regulatory requirements. 

Evotec has never paid or declared any cash dividends on its ordinary shares, and does not anticipate paying any cash dividends on its ordinary shares in the foreseeable future. Evotec intends to retain all available funds and any future earnings and reinvest them in the company’s further growth strategy to better leverage longterm growth and sustainability.

Under German law, Evotec may pay dividends only from the distributable profit (Bilanzgewinn) reflected in its unconsolidated financial statements (as opposed to the consolidated financial statements for Evotec and its subsidiaries) prepared in accordance with the principles set forth in the German Commercial Code (Handelsgesetzbuch) and adopted by the Evotec Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat), or, as the case may be, by the shareholders of Evotec in a general shareholders’ meeting. In addition, under German law Evotec may not pay dividends before annual profits exceed the losses carried forward. 

All of the shares represented by the ADSs offered in USA generally have the same dividend rights as all of Evotec's other outstanding shares.

 

TOP